7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
2 citations,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
63 citations,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
6 citations,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
40 citations,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
489 citations,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
70 citations,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
April 2018 in “Journal of Investigative Dermatology” Blocking a specific immune cell signal can trigger hair growth.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
1 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
May 2019 in “Australasian Journal of Dermatology” The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
23 citations,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
9 citations,
December 2017 in “The Journal of Allergy and Clinical Immunology” New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
2 citations,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
1 citations,
July 2023 in “Journal of Clinical Medicine” Different causes of beard hair loss have various treatments, including medications, lifestyle changes, and procedures to stimulate hair growth.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
6 citations,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.